Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of bladder instillation with Camrelizumab and compare to
the efficacy of intravesical therapy with intravenous therapy using Camrelizumab in patients
with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fudan University
Collaborators:
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Shanghai Shen Kang Hospital Development Center